CD8+ T-cell receptor recognizing influenza-derived peptides presented on MHC class I (Influenza-specific CD8+ TCR)

CD8+ T-cell receptors (TCRs) that recognize influenza-derived peptides presented on MHC class I molecules are central to the cellular immune response against influenza virus infection. These receptors, found on cytotoxic T lymphocytes, specifically identify viral fragments—such as the highly conserved M1 58-66 peptide—displayed by human leukocyte antigen (HLA) molecules like HLA-A*02:01 (Gras et al., 2009, Nature). Upon recognition, the TCR initiates a signaling cascade that leads to the destruction of infected host cells through the release of perforin and granzymes, thereby limiting viral replication and spread (Thomas et al., 2006, Journal of Immunology). These TCRs are primary targets for the development of universal influenza vaccines and adoptive T-cell therapies, which seek to leverage the cross-reactive potential of T cells against diverse influenza strains (Valkenburg et al., 2014, Nature Communications). Therapeutic strategies often focus on identifying high-affinity TCR sequences that can be engineered into patient T cells to provide robust, long-term immunity (Valkenburg et al., 2016, Current Opinion in Virology). However, challenges such as viral escape through peptide mutation and the risk of off-target reactivity with self-peptides remain significant hurdles in clinical application.

Other names

Influenza-specific T-cell receptorFlu-specific CD8+ TCRMHC-I restricted influenza TCRInfluenza-specific cytotoxic T-lymphocyte receptor

Recognition of influenza viral peptides (e.g., M1 58-66 or NP 366-374) presented by MHC class I molecules (e.g., HLA-A*02:01) on the surface of infected cells, triggering T-cell receptor signaling, the release of cytotoxic granules (perforin/granzymes), and targeted lysis of the infected cell.